PL2780717T3 - Oznaczenia adrenomeduliny i sposoby do oznaczania dojrzałej adrenomeduliny - Google Patents

Oznaczenia adrenomeduliny i sposoby do oznaczania dojrzałej adrenomeduliny

Info

Publication number
PL2780717T3
PL2780717T3 PL12791143T PL12791143T PL2780717T3 PL 2780717 T3 PL2780717 T3 PL 2780717T3 PL 12791143 T PL12791143 T PL 12791143T PL 12791143 T PL12791143 T PL 12791143T PL 2780717 T3 PL2780717 T3 PL 2780717T3
Authority
PL
Poland
Prior art keywords
adrenomedullin
assays
methods
determining mature
determining
Prior art date
Application number
PL12791143T
Other languages
English (en)
Inventor
Andreas Bergmann
Original Assignee
Sphingotec Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sphingotec Gmbh filed Critical Sphingotec Gmbh
Publication of PL2780717T3 publication Critical patent/PL2780717T3/pl

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54306—Solid-phase reaction mechanisms
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1725—Complement proteins, e.g. anaphylatoxin, C3a or C5a
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/26—Infectious diseases, e.g. generalised sepsis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/70—Mechanisms involved in disease identification
    • G01N2800/7095—Inflammation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
PL12791143T 2011-11-16 2012-11-16 Oznaczenia adrenomeduliny i sposoby do oznaczania dojrzałej adrenomeduliny PL2780717T3 (pl)

Applications Claiming Priority (12)

Application Number Priority Date Filing Date Title
EP11189452 2011-11-16
EP11189447 2011-11-16
EP11189449 2011-11-16
EP11189450 2011-11-16
EP11189448 2011-11-16
EP12160016 2012-03-16
EP12160018 2012-03-16
EP12160015 2012-03-16
EP12160014 2012-03-16
EP12160017 2012-03-16
EP12186449 2012-09-27
EP12791143.6A EP2780717B1 (en) 2011-11-16 2012-11-16 Adrenomedullin assays and methods for determining mature adrenomedullin

Publications (1)

Publication Number Publication Date
PL2780717T3 true PL2780717T3 (pl) 2017-06-30

Family

ID=47148677

Family Applications (1)

Application Number Title Priority Date Filing Date
PL12791143T PL2780717T3 (pl) 2011-11-16 2012-11-16 Oznaczenia adrenomeduliny i sposoby do oznaczania dojrzałej adrenomeduliny

Country Status (15)

Country Link
US (4) US9304127B2 (pl)
EP (1) EP2780717B1 (pl)
JP (1) JP6336911B2 (pl)
CN (1) CN104067130B (pl)
DK (1) DK2780717T3 (pl)
ES (1) ES2617211T3 (pl)
HR (1) HRP20170427T1 (pl)
HU (1) HUE032648T2 (pl)
MY (5) MY175997A (pl)
PL (1) PL2780717T3 (pl)
PT (1) PT2780717T (pl)
RS (1) RS55804B1 (pl)
RU (1) RU2657517C2 (pl)
SI (1) SI2780717T1 (pl)
WO (1) WO2013072509A1 (pl)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS58880B1 (sr) 2011-11-16 2019-08-30 Adrenomed Ag Antitelo na adrenomedulln (adm) ili fragment antitela na adm ili struktura antitela na adm bez ig za sprečavanje ili smanjenje disfunkcije organa ili insuficijencije organa u pacijentu koji ima hroničnu ili akutnu bolest ili akutno stanje
DK2780370T3 (da) 2011-11-16 2019-10-28 Adrenomed Ag Anti-adrenomedullin (adm)-antistof eller anti-adm-antistoffragment eller anti-adm-ikke-ig skelet til anvendelse i terapi af en akut sygdom eller akut tilstand af en patient til at stabilisere kredsløbet
SG11201402354YA (en) 2011-11-16 2014-06-27 Adrenomed Ag Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for regulating the fluid balance in a patient having a chronic or acute disease
KR101548284B1 (ko) * 2014-05-23 2015-08-28 주식회사 나노엔텍 신규한 시료 내 검출대상물의 검출방법 및 그를 이용한 검출키트
EP3380845A1 (en) * 2015-11-27 2018-10-03 B.R.A.H.M.S GmbH MR-proADM AS MARKER FOR THE EXTRACELLULAR VOLUME STATUS OF A SUBJECT
WO2018029213A1 (en) * 2016-08-09 2018-02-15 B.R.A.H.M.S Gmbh Histones and/or proadm as markers indicating organ dysfunction
EP3309550A1 (en) * 2016-10-12 2018-04-18 sphingotec GmbH Method for the detection of apolipoprotein e4
MX2019007107A (es) * 2016-12-16 2019-10-21 Adrenomed Ag Anticuerpo anti-adrenomedulina (adm) o fragmento de anticuerpo anti-adm o supercontigo sin ig anti-adm para su uso en intervencion y terapia de congestion en un paciente con necesidad del mismo.
JP6862963B2 (ja) * 2017-03-17 2021-04-21 東ソー株式会社 ペプチドの吸着抑制剤
WO2018216580A1 (ja) * 2017-05-22 2018-11-29 東ソー株式会社 アドレノメデュリン濃度変動による予後予測の情報提供方法及びその試薬
JP7366007B2 (ja) * 2017-09-13 2023-10-20 ベー．エル．アー．ハー．エム．エス ゲゼルシャフト ミット ベシュレンクテル ハフツング プロアドレノメジュリンに基づく輸液療法のガイダンスのための方法
EP3971573A1 (en) * 2017-09-13 2022-03-23 B.R.A.H.M.S GmbH Proadrenomedullin as a marker for abnormal platelet levels
CN111065922A (zh) * 2017-09-13 2020-04-24 B.R.A.H.M.S有限公司 肾上腺髓质素原作为危重病患者的肾脏替代治疗的指标
KR20250004928A (ko) * 2017-09-25 2025-01-08 아드레노메드 아게 질병의 증상의 치료 또는 예방에 사용하기 위한 항-아드레노메둘린 (adm) 결합제
WO2019077082A1 (en) 2017-10-18 2019-04-25 Adrenomed Ag SURVEILLANCE OF THERAPY UNDER TREATMENT WITH ANTI-ADRENOMEDULIN BINDER (ADM)
EP3749959A1 (en) * 2018-02-08 2020-12-16 sphingotec GmbH Adrenomedullin (adm) for diagnosis and/or prediction of dementia and anti-adrenomedullin binder for use in therapy or prevention of dementia
WO2019167128A1 (ja) * 2018-02-27 2019-09-06 株式会社 島津製作所 サンドイッチ型免疫測定法
WO2019167830A1 (ja) * 2018-02-27 2019-09-06 株式会社 島津製作所 ＡＰＰ６６９－ｘのＮ末端を特異的に認識する抗体、及び免疫測定法
EP3608673A1 (en) * 2018-08-08 2020-02-12 B.R.A.H.M.S GmbH Pro-adm for prognosing the risk of a medical condition requiring hospitalization in patients with symptoms of infectious disease
WO2020179224A1 (ja) * 2019-03-01 2020-09-10 株式会社島津製作所 Ａｐｐ６６９－７１１の測定方法、及び測定用キット
CN110470771B (zh) * 2019-09-05 2021-06-01 清华大学 一种评价转基因植物食用安全性的方法
WO2025133235A1 (en) * 2023-12-22 2025-06-26 Pam Theragnostics Gmbh Adm-gly as marker for early predicting sepsis

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
AU634716B2 (en) 1988-08-01 1993-03-04 Ciba Corning Diagnostics Corp. Method for detection of an analyte using acridinium esters and liposomes
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
WO1991010741A1 (en) 1990-01-12 1991-07-25 Cell Genesys, Inc. Generation of xenogeneic antibodies
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
JPH06508511A (ja) 1990-07-10 1994-09-29 ケンブリッジ　アンティボディー　テクノロジー　リミティド 特異的な結合ペアーの構成員の製造方法
EP0746609A4 (en) 1991-12-17 1997-12-17 Genpharm Int NON-HUMAN TRANSGENIC ANIMALS CAPABLE OF PRODUCING HETEROLOGOUS ANTIBODIES
JP2774769B2 (ja) * 1993-04-26 1998-07-09 賢治 寒川 アドレノメデュリン
CA2229741C (en) 1995-08-18 2012-05-08 The Government Of The United States Of America Functional role of adrenomedullin (am) and the gene-related product (pamp) in human pathology and physiology
CA2242308A1 (en) 1997-12-08 1999-06-08 Smithkline Beecham Laboratoires Pharmaceutiques Novel compounds
DE19847690A1 (de) 1998-10-15 2000-04-20 Brahms Diagnostica Gmbh Verfahren und Substanzen für die Diagnose und Therapie von Sepsis und sepsisähnlichen systemischen Infektionen
US6818418B1 (en) 1998-12-10 2004-11-16 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
AU774725B2 (en) 1999-09-10 2004-07-08 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Determination of adrenomedullin-binding proteins
CA2414073A1 (en) 2001-05-04 2002-11-14 Gunars E. Valkirs Diagnostic markers of acute coronary syndromes and methods of use thereof
RU2209071C2 (ru) * 2001-08-08 2003-07-27 Ростовский НИИ акушерства и педиатрии Способ лечения сепсиса у детей
IL160289A0 (en) 2001-08-30 2004-07-25 Biorexis Pharmaceutical Corp Modified transferrin fusion proteins
US6864237B2 (en) 2002-05-17 2005-03-08 Ping Wang Treatment of shock using adrenomedullin and adrenomedullin binding protein-1
ES2528254T3 (es) 2002-06-07 2015-02-05 Dyax Corp. Polipéptidos de dominio Kunitz modificado y su uso para reducir la isquemia o el inicio de una respuesta inflamatoria sistémica asociada con un procedimiento quirúrgico
DE10316583A1 (de) * 2003-04-10 2004-10-28 B.R.A.H.M.S Aktiengesellschaft Bestimmung eines midregionalen Proadrenomedullin-Teilpeptids in biologischen Flüssigkeiten zu diagnostischen Zwecken, sowie Immunoassays für die Durchführung einer solchen Bestimmung
JP2007523844A (ja) 2003-04-25 2007-08-23 ジェノバ・リミテッド 心臓血管障害において減少する分泌ポリペプチド種
US6884781B2 (en) * 2003-05-16 2005-04-26 Ping Wang Treatment of shock using adrenomedullin binding protein-1
CA2537668A1 (en) * 2003-09-29 2005-04-14 Biosite Incorporated Methods and compositions for the diagnosis of sepsis
WO2005040229A2 (en) 2003-10-24 2005-05-06 Avidia, Inc. Ldl receptor class a and egf domain monomers and multimers
US20100028995A1 (en) 2004-02-23 2010-02-04 Anaphore, Inc. Tetranectin Trimerizing Polypeptides
WO2006027147A2 (en) 2004-09-09 2006-03-16 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with adrenomedullin receptor (amdr)
US8278262B2 (en) 2004-09-21 2012-10-02 Biontech Ag Use of microproteins as tryptase inhibitors
US9829494B2 (en) 2005-12-01 2017-11-28 Adrenomed Ag Methods of treatment using ADM antibodies
WO2008021431A2 (en) * 2006-08-14 2008-02-21 Xdx, Inc. Methods and compositions for diagnosing and monitoring the status of transplant rejection and immune disorders
ES2373832T3 (es) 2007-12-19 2012-02-09 Affibody Ab Polipéptido derivado de proteína a y capaz de unirse a pdgf.
CA2742241C (en) 2008-11-03 2019-12-10 Molecular Partners Ag Binding proteins inhibiting the vegf-a receptor interaction
BR112012004314A2 (pt) 2009-08-27 2016-11-29 Covagen Ag compostos de ligação a il-17 e usos medicinais desses compostos
BR112012014417B1 (pt) 2009-12-14 2021-11-09 Scil Proteins Gmbh Proteínas ubiquitinas modificadas tendo uma atividade de ligação específica para o extradomínio b de fibronectina
DE102010040035A1 (de) 2010-03-04 2011-09-08 Robert Bosch Gmbh Verbesserungen der Rückwärts-Analyse zur Bestimmung von Fehlermaskierungsfaktoren
WO2011127176A2 (en) 2010-04-06 2011-10-13 The Children's Research Institute Methods for treating or screening for compounds for the treatment of sepsis
NZ603226A (en) 2010-04-30 2015-02-27 Alexion Pharma Inc Anti-c5a antibodies and methods for using the antibodies
EP2580236B1 (en) 2010-06-08 2019-04-03 Pieris Pharmaceuticals GmbH Tear lipocalin muteins binding il-4 r alpha
FR2964103B1 (fr) * 2010-08-30 2018-11-23 Universite D'aix-Marseille Anticorps se liant a l'adrenomedulline et aux recepteurs de l'adrenomedulline et leurs utilisations comme medicament
US11067586B2 (en) * 2011-11-16 2021-07-20 Sphingotec Gmbh Adrenomedullin assays and methods for determining mature adrenomedullin

Also Published As

Publication number Publication date
MY174894A (en) 2020-05-20
MY192113A (en) 2022-07-28
EP2780717A1 (en) 2014-09-24
US12228581B2 (en) 2025-02-18
US20130195875A1 (en) 2013-08-01
MY175997A (en) 2020-07-20
MY178654A (en) 2020-10-20
RU2014123987A (ru) 2015-12-27
US9140696B2 (en) 2015-09-22
RS55804B1 (sr) 2017-08-31
US20240085438A1 (en) 2024-03-14
WO2013072509A1 (en) 2013-05-23
PT2780717T (pt) 2017-02-16
HUE032648T2 (en) 2017-10-30
DK2780717T3 (en) 2017-02-13
US9535060B2 (en) 2017-01-03
JP2014533827A (ja) 2014-12-15
SI2780717T1 (sl) 2017-05-31
US20130195874A1 (en) 2013-08-01
US9304127B2 (en) 2016-04-05
JP6336911B2 (ja) 2018-06-06
ES2617211T3 (es) 2017-06-15
CN104067130B (zh) 2017-02-22
US20140322824A1 (en) 2014-10-30
EP2780717B1 (en) 2016-12-21
HRP20170427T1 (hr) 2017-06-16
RU2657517C2 (ru) 2018-06-14
MY174877A (en) 2020-05-20
HK1202624A1 (en) 2015-10-02
CN104067130A (zh) 2014-09-24

Similar Documents

Publication Publication Date Title
SI2780717T1 (sl) Adrenomedulinski testi in postopki za določevanje zrelega adrenomedulina
IL259826A (en) Anti-alphabetatisiar antibody
ZA201307983B (en) Anti-b7-h3 antibody
GB201103955D0 (en) Antibodies
GB201112056D0 (en) Antibodies
EP2736330A4 (en) COMPOUNDS AND METHODS
EP2768983A4 (en) METHODS OF IDENTIFYING MUTATIONS ASSOCIATED WITH DISEASES
ZA201404319B (en) Biomarkers and parameters for preeclampsia
EP2747560A4 (en) CONNECTIONS AND METHODS
EP2736332A4 (en) CONNECTIONS AND METHODS
EP2736329A4 (en) COMPOUNDS AND METHODS
EP2637017A4 (en) METHOD FOR MEASURING FILLING CAPACITY
ZA201306389B (en) Food analogs and methods for making food analogs
EP2791653A4 (en) PROCESS FOR OPTIMIZED SCATTEROMETRY
EP2685257A4 (en) METHOD OF ANALYSIS
GB201117538D0 (en) Methods
TWI563004B (en) Anti-hxcr1 antibody
AP2013007021A0 (en) Method for assaying hydrocarbons
IL228073A0 (en) Method for the determination of polysorbate
IL226429A0 (en) An in vitro method for determining the presence of type ii pyrethroids
EP2683996A4 (en) SYSTEMS AND PROCESSES FOR FERROUS ENHANCEMENT
IL231327A0 (en) Methods for increasing the function of osteoblasts
EP2757373A4 (en) METHOD FOR MEASURING ANTI-WT1 ANTIBODIES
GB201101219D0 (en) Method
EP2714074A4 (en) ANTIBODIES AGAINST EMR1